 Home > Coatings News > Paints and Coatings Market > Evonik releases 2020 full-year financial report: Andorra's epidemic is difficult, and it is back on the growth track

Evonik releases 2020 full-year financial report: Andorra's epidemic is difficult, and it is back on the growth track

 Last Update: 2021-03-23
 Source: Internet
 Author: User

Tags

logistics

create 3d model

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Achieve the 2020 target: adjusted EBITDA of 1.
9 billion euros and sales of more than 12 billion euros
Free cash flow increased significantly from last year
Expected target for 2021 : Adjusted EBITDA will increase to between 2 billion and 2.
3 billion euros

Achieve the 2020 target: adjusted EBITDA of 1.
9 billion euros and sales of more than 12 billion euros

Free cash flow increased significantly from last year

Expected target for 2021 : Adjusted EBITDA will increase to between 2 billion and 2.
3 billion euros

Evonik released its 2020 financial report, and the company reached its full-year financial target.
Global production and logistics activities are guaranteed, and various employee protection measures are continuously implemented.
In 2021 , Evonik will return to the growth track.

In 2021 , Evonik will return to the growth track.

Couleman, Chairman of Evonik Industries Group, said: "We have withstood the test of the tug-of-war of the epidemic, successfully tided over the difficulties, and achieved the expected goals.
"

Evonik is one of the few companies to release a full-year outlook in the spring of 2020 .
2020 years before interest, taxes, depreciation and amortization profit (after adjustment Group EBITDA ) was 19.

1 million euros ( 2019 year: 21.

Evonik is one of the few companies to release a full-year outlook in the spring of 2020 .

"During this crisis, we focused more on the transformation of specialty chemicals business and achieved fruitful results.

Evonik is working hard to promote more growth projects, including the expansion of the production scale of its special liposomes, the liposome for mRNA new crown vaccine is essential .

At present, about 35% of Evonik ’s sales come from products with more sustainable benefits than competing products, and they are also “next-generation solutions” that are urgently needed for future technological development.

In 2021 , Evonik expects adjusted EBITDA to rise to between 2 billion euros and 2.

Last year, Evonik's free cash flow increased to 780 million euros, and the cash conversion rate increased to more than 40% .

In 2020 , the group's net income fell to 465 million euros.

Evonik will ensure the distribution of dividends.

Performance of business divisions Performance of business divisions

Specialty Additives Business Unit: Specialty Additives Business Unit: In 2020 , sales in this segment will fall by 5% to 3.

Nutrition and Consumer Chemicals Business Unit: Nutrition and Consumer Chemicals Business Unit: In 2020 , sales in this sector will increase by 2% to 2.

Smart Materials Business Unit: Smart Materials Business Unit: In 2020 , sales in this sector will fall by 4% to 3.

Functional Materials Business Department: Functional Materials Business Department: In 2020 , sales in this sector fell by 25% to 1.
98 billion euros.
Affected by the decline in market demand, especially the decline in demand in the automotive and fuel industries, the sales of carbon four series products have fallen.
The industry capacity utilization rate of the super absorbent business has improved, but it is still below the average level, which has a negative impact on business development.
The adjusted EBITDA of the functional materials division fell by 65% to 88 million euros.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.